BioMark Diagnostics Inc. (CNQ: BUX.CN) Stock Competitors & Peer Comparison

BioMark Diagnostics Inc. (CNQ: BUX.CN) plays a significant role within the Healthcare sector. Its performance on the CNQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BUX.CN stands at 47.9M. In comparison, TMO.TO has a market cap of 359.5B. Regarding current trading prices, BUX.CN is priced at CA$0.45 on the CNQ, while TMO.TO trades at CA$24.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BUX.CN currently has a P/E ratio of -24.03, whereas TMO.TO's P/E ratio is 34.82. In terms of profitability, BUX.CN's ROE is -2.51%, compared to TMO.TO's ROE of N/A. Regarding short-term risk, BUX.CN is less volatile compared to TMO.TO. This indicates lower risk in terms of short-term price fluctuations for BUX.CN.Check TMO.TO's competition here

BioMark Diagnostics Inc. (CNQ: BUX.CN) plays a significant role within the Healthcare sector. Its performance on the CNQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BUX.CN stands at 47.9M. In comparison, TMO.NE has a market cap of 341B. Regarding current trading prices, BUX.CN is priced at CA$0.45 on the CNQ, while TMO.NE trades at CA$24.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BUX.CN currently has a P/E ratio of -24.03, whereas TMO.NE's P/E ratio is 1.81. In terms of profitability, BUX.CN's ROE is -2.51%, compared to TMO.NE's ROE of +0.13%. Regarding short-term risk, BUX.CN is less volatile compared to TMO.NE. This indicates lower risk in terms of short-term price fluctuations for BUX.CN.Check TMO.NE's competition here

BioMark Diagnostics Inc. (CNQ: BUX.CN) plays a significant role within the Healthcare sector. Its performance on the CNQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BUX.CN stands at 47.9M. In comparison, EDT.TO has a market cap of 284.7M. Regarding current trading prices, BUX.CN is priced at CA$0.45 on the CNQ, while EDT.TO trades at CA$0.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BUX.CN currently has a P/E ratio of -24.03, whereas EDT.TO's P/E ratio is -7.53. In terms of profitability, BUX.CN's ROE is -2.51%, compared to EDT.TO's ROE of +0.51%. Regarding short-term risk, BUX.CN is less volatile compared to EDT.TO. This indicates lower risk in terms of short-term price fluctuations for BUX.CN.Check EDT.TO's competition here

BioMark Diagnostics Inc. (CNQ: BUX.CN) plays a significant role within the Healthcare sector. Its performance on the CNQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BUX.CN stands at 47.9M. In comparison, AKU.TO has a market cap of 45.2M. Regarding current trading prices, BUX.CN is priced at CA$0.45 on the CNQ, while AKU.TO trades at CA$0.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BUX.CN currently has a P/E ratio of -24.03, whereas AKU.TO's P/E ratio is -0.14. In terms of profitability, BUX.CN's ROE is -2.51%, compared to AKU.TO's ROE of -5.50%. Regarding short-term risk, BUX.CN is less volatile compared to AKU.TO. This indicates lower risk in terms of short-term price fluctuations for BUX.CN.Check AKU.TO's competition here

BioMark Diagnostics Inc. (CNQ: BUX.CN) plays a significant role within the Healthcare sector. Its performance on the CNQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BUX.CN stands at 47.9M. In comparison, IZO.CN has a market cap of 8M. Regarding current trading prices, BUX.CN is priced at CA$0.45 on the CNQ, while IZO.CN trades at CA$0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BUX.CN currently has a P/E ratio of -24.03, whereas IZO.CN's P/E ratio is -3.50. In terms of profitability, BUX.CN's ROE is -2.51%, compared to IZO.CN's ROE of +0.40%. Regarding short-term risk, BUX.CN is less volatile compared to IZO.CN. This indicates lower risk in terms of short-term price fluctuations for BUX.CN.Check IZO.CN's competition here

BioMark Diagnostics Inc. (CNQ: BUX.CN) plays a significant role within the Healthcare sector. Its performance on the CNQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BUX.CN stands at 47.9M. In comparison, SZLS.TO has a market cap of 4.9M. Regarding current trading prices, BUX.CN is priced at CA$0.45 on the CNQ, while SZLS.TO trades at CA$0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BUX.CN currently has a P/E ratio of -24.03, whereas SZLS.TO's P/E ratio is -1.61. In terms of profitability, BUX.CN's ROE is -2.51%, compared to SZLS.TO's ROE of +4.82%. Regarding short-term risk, BUX.CN is similarly volatile compared to SZLS.TO. This indicates similar risk in terms of short-term price fluctuations for BUX.CN.Check SZLS.TO's competition here

BioMark Diagnostics Inc. (CNQ: BUX.CN) plays a significant role within the Healthcare sector. Its performance on the CNQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BUX.CN stands at 47.9M. In comparison, SCRN.CN has a market cap of 1.5M. Regarding current trading prices, BUX.CN is priced at CA$0.45 on the CNQ, while SCRN.CN trades at CA$0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BUX.CN currently has a P/E ratio of -24.03, whereas SCRN.CN's P/E ratio is -0.25. In terms of profitability, BUX.CN's ROE is -2.51%, compared to SCRN.CN's ROE of -14.30%. Regarding short-term risk, BUX.CN is similarly volatile compared to SCRN.CN. This indicates similar risk in terms of short-term price fluctuations for BUX.CN.Check SCRN.CN's competition here

BioMark Diagnostics Inc. (CNQ: BUX.CN) plays a significant role within the Healthcare sector. Its performance on the CNQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BUX.CN stands at 47.9M. In comparison, MEDV.NE has a market cap of 810.6K. Regarding current trading prices, BUX.CN is priced at CA$0.45 on the CNQ, while MEDV.NE trades at CA$0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BUX.CN currently has a P/E ratio of -24.03, whereas MEDV.NE's P/E ratio is -0.09. In terms of profitability, BUX.CN's ROE is -2.51%, compared to MEDV.NE's ROE of +2.13%. Regarding short-term risk, BUX.CN is less volatile compared to MEDV.NE. This indicates lower risk in terms of short-term price fluctuations for BUX.CN.Check MEDV.NE's competition here